Searchable abstracts of presentations at key conferences in endocrinology

ea0029p353 | Clinical case reports - Pituitary/Adrenal | ICEECE2012

Long-term efficacy and safety of pasireotide in Cushing’s disease: a 36-month case report

Ning G. , Wang W. , Maldonado M. , Trovato A. , Zhou W.

Background: A recent, large phase III study (n=162) showed that treatment with pasireotide rapidly decreased urinary free cortisol (UFC) levels and improved signs and symptoms in patients with Cushing’s disease. Here, we report the experience of a patient enrolled in this trial who received pasireotide for 36 months.Results: A 31-year-old male presented in June 2008 with persistent Cushing’s disease despite two previous pituitary surgica...

ea0029p507 | Diabetes | ICEECE2012

QRFP43 and its fragment 26RFa both promote β-cell survival but differently regulate insulin secretion and glucose uptake in pancreatic β-cells and human pancreatic islets

Trovato L. , Settanni F. , Gallo D. , Gargantini E. , Bergandi L. , Ong H. , Ghigo E. , Granata R.

RFamides are a family of peptides containing arginine-phenylalanine-amide at their C terminus. A novel 43-amino acid RFamide, named QRFP43, and a shorter endogenous peptide 26RFa, were discovered and identified as ligands of the G protein-coupled receptor GPR103. Different studies have shown that RFamides, such as neuropeptide FF and QRFP43 and 26RFa, play a role in food intake, thermogenesis and energy homeostasis. Here, we investigated the effects of QRFP peptides on surviva...

ea0022p702 | Obesity | ECE2010

Acylated, unacylated ghrelin and obestatin regulation during oral glucose tolerance test in obese prepubertal and pubertal children

Prodam Flavia , Bellone Simonetta , Petri Antonella , Trovato Letizia , Genoni Giulia , Dondi Elena , Demarchi Irene , Bona Gianni

Physiological role of acylated ghrelin (AG), unacylated ghrelin (UAG) and obestatin is poorly understood especially in childhood. To understand their biological implications in obesity and metabolic syndrome (MS), we measured AG, UAG, obestatin, at fasting and every 60′ during oral glucose tolerance test (OGTT) in 60 prepubertal (PP–OB; 32) and pubertal (P-OB; 28) children. Paediatric IDF 2007 criteria was used to identifying MS. In PP-OB group, 20 (62.5%) children ...

ea0014oc6.1 | Cardiovascular endocrinology | ECE2007

Growth hormone-releasing hormone prevents cardiomyocyte apoptosis and activated PI3K/AKT, ERK1/2 and CREB signaling pathways

Granata Riccarda , Trovato Letizia , Destefanis Silvia , Settanni Fabio , Annunziata Marta , Gallo Davide , Ghigo Ezio

The hypothalamic hormone growth hormone-releasing hormone (GHRH), has been shown to function via its receptor splice variants as an autocrine/paracrine growth factor in normal and malignant cell lines and tissues, besides positively regulating growth hormone (GH) synthesis and secretion from the pituitary. Moreover, GHRH antagonists are known to suppress the proliferation of a wide variety of cancer cells through mechanisms yet to be fully elucidated. Aim of this study was to ...

ea0032p853 | Pituitary – Clinical (<emphasis role="italic">Generously supported by IPSEN</emphasis>) | ECE2013

Evaluation of late-night salivary cortisol during a Phase III study with pasireotide in patients with Cushing's disease

Newell-Price John , Petersenn Stephan , Pivonello Rosario , Findling James , Fleseriu Maria , Trovato Andrew , Hughes Gareth , Ligueros-Saylan Monica , Biller Beverly

Introduction: Generously supported by IPSEN)-->Measurement of salivary cortisol is a simple, convenient, accurate and reproducible technique with potential value during the diagnosis/management of hypercortisolism. Current analysis evaluates changes in late-night salivary cortisol (LNSC) during pasireotide treatment in patients with Cushing’s disease (CD).Methods: A 12 m, Phase III study enrolled 162 adult...

ea0029p1405 | Pituitary Clinical | ICEECE2012

Long-term use of pasireotide in Cushing’s disease: 24-month safety results from a randomized phase III study

Bertherat J , Ludlam W , Pivonello R , Maldonado M , Trovato A , Hughes G , Gu F , Schopohl J , Salgado L

Introduction: Rapid and sustained decreases in UFC and significant improvements in signs and symptoms were seen in a large, randomized, 12-month phase III study of pasireotide in Cushing’s disease. The safety profile of pasireotide was found to be similar to that of other somatostatin analogues, with the exception of hyperglycemia-related AEs (reported in 72.8% of patients). This abstract reports safety data from a 12-month extension to this phase III trial.<p class="...

ea0029p1410 | Pituitary Clinical | ICEECE2012

Long-term pasireotide use leads to improvements in the biochemical parameters of Cushing’s disease: 24-month results from a randomized phase III study

Schopohl J , Bertherat J , Ludlam W , Maldonado M , Trovato A , Hughes G , Gu F , Salgado L , Pivonello R

Introduction: The large, randomized, phase III study of pasireotide in Cushing’s disease found that pasireotide treatment resulted in rapid and sustained decreases in UFC levels and in significant improvements in signs and symptoms over 12 months of treatment. A 12-month extension of this trial has recently completed, and the results are reported here.Methods: Patients with persistent/recurrent or de novo (if not surgical candidates) Cushing&...

ea0026p381 | Thyroid (non cancer) | ECE2011

ESE Young Investigator Award

Moia Stefania , Prodam Flavia , Monzani Alice , Bellone Simonetta , Riccomagno Stefania , Walker Gillian , Trovato Letizia , Roccio Marta , Agretti Patrizia , Bona Gianni

TSH receptor (TSHR) is a G-protein-coupled seven-transmembrane domain receptor located in the basolateral membrane of thyroid follicular cells. The activated receptor couples to two major signal transductions pathways: the Gs/adenylate cyclase and the Gq/11/phospholipase C signalling. Many loss of function mutations have been identified in this gene leading to a wide spectrum of thyroid abnormalities, ranging from hyperthyrotropinemia and TSH resistance to severe hypothyroidis...

ea0020oc6.3 | Paediatric Endocrinology/Bone | ECE2009

Ghrelin and obestatin levels in normal weighted and obese prepubertal children

Prodam Flavia , Bellone Simonetta , Trovato Letizia , Grassino Erica , Moia Stefania , De Marchi Irene , De Rienzo Francesca , Bona Gianni

Introduction: Three peptides, acylated ghrelin (AG), unacylated ghrelin (UAG) and obestatin are derived from a common prohormone, preproghrelin by posttranslational processing, originating from endocrine cells in the stomach. Circulating ghrelin levels are decreased in obese subjects and increased by fasting and in patients with anorexia nervosa, but the physiological role of the three peptides is poorly understood in particular in childhood.Aim: In orde...

ea0016p611 | Reproduction | ECE2008

Endometriotic cell proliferation and survival are inhibited by somatostatin analogues and GHRH antagonists

Annunziata Marta , Trovato Letizia , Settanni Fabio , Grande Cristina , Gallo Davide , Camanni Marco , Deltetto Francesco , Ghigo Ezio , Granata Riccarda

Somatostatin (SST) and growth hormone-releasing hormone (GHRH) are hypothalamic hormones that, respectively, inhibit and stimulate pituitary GH secretion. In addition, in peripheral tissues somatostatin and its analogues inhibit, whereas GHRH stimulates, both normal and cancer cell growth and survival. Furthermore, both somatostatin receptor 2 (SSTR-2) and GHRH expression have been shown in normal human endometrium. Endometriosis is a common estrogen-dependent disorder defined...